Toni Choueiri: The story of adaptive IO therapy in RCC

Toni Choueiri recently shared a post by Rana McKay, an Associate Professor of Medicine at UC San Diego, on X, adding:

“The story of adaptive IO therapy in RCC. Not for everyone and overall, not the best strategy.”

Quoting Rana McKay’s post:

“Pooled analysis do adaptive studies of Nivolumab followed by Ipilimumab in RCC. Lower rates of response conversion and CR. Upfront intensification preferred.”

Sources: Toni Choueiri/X and Rana McKay/X

Toni Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School.

Dr. Choueiri is an elected member of the American Society of Clinical Investigation (ASCI). In addition, he is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania.